ETNB News and Press, 89bio Inc. From 05/28/23

2023-05-28 04:18:19 ET Summary ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. The data is very competitive. I have been covering 89bio ( ETNB ) for a few years now. I also added it to the List, but it was not a good idea in 2021....

2023-05-26 11:10:38 ET Summary Questions and comments from readers answered. Lookback timeframes identified. Selection of original list of quality stocks from which to select best. Technique of buying and selling after the best stocks are identified. I hadn't ori...

2023-05-23 13:49:21 ET San Francisco-based 89bio ( NASDAQ: ETNB ) started a phase 3 trial of pegozafermin to treat patients with severe hypertriglyceridemia (SHTG). SHTG is a condition in which there is high level of a certain type of fat called triglycerides (TGs) in the bloo...

SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Pha...

2023-05-09 08:19:46 ET Summary I present additional information about my methodology for finding the best stocks. Some of the technical tools I use to make final decisions to buy or sell. The leadership of certain stocks and sectors changes occasionally, and we can take this i...

2023-05-07 10:05:43 ET Summary AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY. However, SYMMETRY will prove its cirrhosis activity, so there may we...

2023-05-04 17:25:58 ET 89bio press release ( NASDAQ: ETNB ): Q1 GAAP EPS of -$0.54 in-line. As of March 31, 2023, 89bio had cash, cash equivalents, and short-term investments totaling $480.9 million. For further details see: 89bio GAAP EPS of -$0.54 in-line

– Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3; discussions with regulatory agencies planned for the second half of 2023 – &#...

2023-05-04 03:08:32 ET Summary My journey on the road to finding the best portfolio. My early attempts to find the best stocks in which to invest. My success in finding the best methods. I feel it is about time to publish my latest stock recommendations as I have, I ...

2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...